October 2016 #3 - HCV
Read online or forward

Enjoy our HCV news!

Hepatitis C virus (HCV) is estimated to chronically infect 180 million people worldwide.

According to WHO, 15 to 30% of these chronically infected persons will develop cirrhosis and hepatocellular carcinoma (HCC). Approximately 700 000 persons die each year from HCV-related liver diseases.

The recent advances in research have made the development of new efficient direct acting antivirals (DAAs) possible that revolutionized the field of hepatitis C treatment with sustained virological responses higher than 90% for all genotypes and subgroups of patients. Despite the high efficacy of these new DAAs, HCV remains a real global burden and the search for an efficient vaccine is still ongoing.

The new EASL Recommendations on Treatment of Hepatitis C 2016 were released on 22 September and live streamed from Paris. At the same time, EASL also organised a special conference on HCV in Paris, where leading experts provided the latest updates in the field as well as critical reviews and analysis on the best way to achieve HCV elimination.

Discover HCV EASL news

EASL members can now access all conference material via the LiverTreeTM.
Discover or re-discover presentations, ePosters, abstracts and more!


Download our free 2016 EASL Recommendations on Treatment of Hepatitis C

Then watch the EASL Recommendations on Youtube and listen to the panel discussion.

EASL will host a monothematic conference on Nutrition in liver disease in November in Ljubljana, covering different aspects of nutrition-induced hepatopathies.
Find out about the challenges associated to cirrhosis, one of the main HCV-related liver diseases. 

The EASL Office


The Home of Hepatology

7 rue Daubin
CH 1203 Geneva
+41 22 807 03 60

This message is sent to <<Email Address>> - Why did I get this message

Update subscription preferences || Unsubscribe

You can sign in at any time by visiting the Newsletter section of our website.